Pharmacokinetic changes of psychotropic drugs in patients with liver disease: Implications for dose adaptation

Drug Safety

Volumn 32, Issue 7, 2009, Pages 561-578

  Schlatter, Chantal ^a   Egger, Sabin S ^a   Tchambaz, Lydia ^a   Krhenbhl, Stephan ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIPARKINSON AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; CYTOCHROME P450; ETIRACETAM; FLURAZEPAM; GABAPENTIN; LITHIUM; LORAZEPAM; NOOTROPIC AGENT; OXAZEPAM; OXCARBAZEPINE; PHENTERMINE; PHENYLPROPANOLAMINE; PRAMIPEXOLE; PREGABALIN; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; SEDATIVE AGENT; SEROTONIN UPTAKE INHIBITOR; SULPIRIDE; TEMAZEPAM; TIAPRIDE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VIGABATRIN;

BIOAVAILABILITY; CONTROLLED STUDY; DOSE CALCULATION; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EXCRETION; HUMAN; LIVER CIRRHOSIS; LIVER METABOLISM; PATIENT SAFETY; PRIORITY JOURNAL; REVIEW; SWITZERLAND; URINARY EXCRETION;

BIOLOGICAL AVAILABILITY; CLINICAL TRIALS AS TOPIC; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIVER CIRRHOSIS; PSYCHOTROPIC DRUGS; SWITZERLAND;

EID: 67649298018     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/00002018-200932070-00003     Document Type: Review

References (167)

1. McLean AJ, Morgan DJ. Clinical pharmacokinetics in patients with liver disease. Clin Pharmacokinet 1991 Jul; 21 (1): 42-69
2. Morgan DJ, McLean AJ. Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease: an update. Clin Pharmacokinet 1995 Nov; 29 (5): 370-91
3. Williams RL, Mamelok RD. Hepatic disease and drug pharmacokinetics. Clin Pharmacokinet 1980 Nov-Dec; 5 (6): 528-47
4. Delco F, Tchambaz L, Schlienger R, et al. Dose adjustment in patients with liver disease. Drug Saf 2005; 28 (6): 529-45
5. Herbert MF. Guide to drug dosage in hepatic disease. In: Holford NHG, editor. Drug data handbook. 3rd ed. Auckland: Adis International, 1998: 179
6. Westphal JF, Brogard JM. Drug administration in chronic liver disease. Drug Saf 1997 Jul; 17 (1): 47-73
7. Verbeeck RK, Horsmans Y. Effect of hepatic insufficiency on pharmacokinetics and drug dosing. Pharm World Sci 1998 Oct; 20 (5): 183-92
8. Rodighiero V. Effects of liver disease on pharmacokinetics: an update. Clin Pharmacokinet 1999 Nov; 37 (5): 399-431
9. Tchambaz L, Schlatter C, Jakob M, et al. Dose adaptation of antineoplastic drugs in patients with liver disease. Drug Saf 2006; 29 (6): 509-22
10. Blendis L, Wong F. The hyperdynamic circulation in cirrhosis: an overview. Pharmacol Ther 2001 Mar; 89 (3): 221-31
11. Krahenbuhl S, Marti U, Grant I, et al. Characterization of mechanisms causing hypoalbuminemia in rats with long-term bile duct ligation. J Hepatol 1995 Jul; 23 (1): 79-86
12. Butler JM, Begg EJ. Free drug metabolic clearance in elderly people. Clin Pharmacokinet 2008; 47 (5): 297-321
13. Crone CC, Gabriel GM, DiMartini A. An overview of psychiatric issues in liver disease for the consultationliaison psychiatrist. Psychosomatics 2006 May-Jun; 47 (3): 188-205
14. Lucena MI, Andrade RJ, Tognoni G, et al. Drug use for non-hepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol 2003 May; 59 (1): 71-6
15. Morgan MH, Read AE. Antidepressants and liver disease. Gut 1972 Sep; 13 (9): 697-701
16. Documed AG. Arzneimittelkompendium der Schweiz [online]. Available from: http://www.kompendium.ch [Accessed 2009 Mar 16]
17. Murray L. editor. Physicians' desk reference (PDR). 59th ed. Montvale (NJ): Thomson PDR, 2005
18. Dollery C. editor. Therapeutic drugs. 2nd ed. Edinburgh: Churchill Livingstone, 1999 19. Thomson Healthcare. Micromedex(R) healthcare series [online]. Available from: http://www.thomsonhc.com [Accessed 2009 Mar 16]
19. Speight TM, Holford NHG, editors. Avery's drug treatment. 4th ed. Auckland: Adis International, 1997
20. Thummel KE, Shen DD, Isoherranen N, et al. Design and optimization of dosage regimens: pharmacokinetic data. In: Brunton LL, editor. Goodman & Gilman's: the pharmacological basis of therapeutics. 11th ed. New York: McGraw-Hill, 2006
21. Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999
22. Be' nichou C, editor. Adverse drug reactions: a practical guide to diagnosis and management. Chichester: John Wiley & Sons Ltd, 1994
23. Bircher J, Sommer W. Klinisch-pharmakologische Datensammlung.
24. Auflage ed. Stuttgart: Wissenschaftliche Verlagsgesellschaft mbH, 1999
25. Buckley PF. Receptor-binding profiles of antipsychotics: clinical strategies when switching between agents. J Clin Psychiatry 2007; 68 Suppl. 6: 5-9
26. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: a meta-analysis. CMAJ 1998 Nov 17; 159 (10): 1245-52
27. Nisoli E, Carruba MO. An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action. Obes Rev 2000 Oct; 1 (2): 127-39
28. Hvidberg EF, Dam M. Clinical pharmacokinetics of anticonvulsants. Clin Pharmacokinet 1976; 1 (3): 161-88
29. Bachmann K, He Y, Sarver JG, et al. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of ethosuximide by human hepatic microsomal enzymes. Xenobiotica 2003 Mar; 33 (3): 265-76
30. Seree EJ, Pisano PJ, Placidi M, et al. Identification of the human and animal hepatic cytochromes P450 involved in clonazepam metabolism. Fundam Clin Pharmacol 1993; 7 (2): 69-75
31. May TW, Korn-Merker E, Rambeck B. Clinical pharmacokinetics of oxcarbazepine. Clin harmacokinet 2003; 42 (12): 1023-42
32. DeVane CL. Pharmacokinetics drug interactions, and tolerability of valproate. Psychopharmacol Bull 2003; 37 Suppl. 2: 25-42
33. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997 Apr; 38 (4): 445-51
34. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin Pharmacokinet 2002; 41 (4): 261-309
35. Kvernmo T, Hartter S, Burger E. A review of the receptorbinding and pharmacokinetic properties of dopamine agonists. Clin Ther 2006 Aug; 28 (8): 1065-78
36. Taavitsainen P, Anttila M, Nyman L, et al. Selegiline metabolism and cytochrome P450 enzymes: in vitro study in human liver microsomes. Pharmacol Toxicol 2000 May; 86 (5): 215-21
37. Yoshii K, Kobayashi K, Tsumuji M, et al. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 2000; 67 (2): 175-84
38. Wojcikowski J, Pichard-Garcia L, Maurel P, et al. Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine. Br J Pharmacol 2003 Apr; 138 (8): 1465-74
39. Mauri MC, Volonteri LS, Colasanti A, et al. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007; 46 (5): 359-88
40. Eiermann B, Engel G, Johansson I, et al. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine. Br J Clin Pharmacol 1997 Nov; 44 (5): 439-46
41. DeVane CL, Nemeroff CB. Clinical pharmacokinetics of quetiapine: an atypical antipsychotic. Clin Pharmacokinet 2001; 40 (7): 509-22
42. Caccia S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000 May; 38 (5): 393-14
43. Sporkert F, Augsburger M, Giroud C, et al. Determination and distribution of clotiapine (Entumine) in human plasma, post-mortem blood and tissue samples from clotiapine- treated patients and from autopsy cases. Forensic Sci Int 2007 Aug 6; 170 (2-3): 193-9
44. Venkatakrishnan K, Greenblatt DJ, Von Moltke LL, et al. Alprazolam is another substrate for human cytochrome P450-3A isoforms [letter]. J Clin Psychopharmacol 1998 Jun; 18 (3): 256
45. Simons FE, Watson WT, Chen XY, et al. The pharmacokinetics and pharmacodynamics of hydroxyzine in patients with primary biliary cirrhosis. J Clin Pharmacol 1989 Sep; 29 (9): 809-15
46. Kilicarslan T, Haining RL, Rettie AE, et al. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metab Dispos 2001 Apr; 29 (4 Pt 1): 460-5
47. Von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996 Feb; 276 (2): 370-9
48. Hellstern A, Hildebrand M, Humpel M, et al. Minimal biliary excretion and enterohepatic recirculation of lormetazepam in man as investigated by a new nasobiliary drainage technique. Int J Clin Pharmacol Ther Toxicol 1990 Jun; 28 (6): 256-61
49. Gaillot J, Le Roux Y, Houghton GW, et al. Critical factors for pharmacokinetics of zopiclone in the elderly and in patients with liver and renal insufficiency. Sleep 1987; 10 Suppl. 1: 7-21
50. Langtry HD, Benfield P. Zolpidem: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990 Aug; 40 (2): 291-313
51. Akutsu T, Kobayashi K, Sakurada K, et al. Identification of human cytochrome p450 isozymes involved in diphenhydramine N-demethylation. Drug Metab Dispos 2007 Jan; 35 (1): 72-8
52. Ganes DA, Midha KK. Identification in in vivo acetylation pathway for N-dealkylated metabolites of doxylamine in humans. Xenobiotica 1987 Aug; 17 (8): 993-9
53. Koyama E, Chiba K, Tani M, et al. Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 1997 Jun; 281 (3): 1199-210
54. Eap CB, Bender S, Gastpar M, et al. Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients. Ther Drug Monit 2000 Apr; 22 (2): 209-14
55. Knapp DR, Gaffney TE, McMahon RE, et al. Studies of human urinary and biliary metabolites of nortriptyline with stable isotope labeling. J Pharmacol Exp Ther 1972 Mar; 180 (3): 784-90
56. Brachtendorf L, Jetter A, Beckurts KT, et al. Cytochrome P450 enzymes contributing to demethylation of maprotiline in man. Pharmacol Toxicol 2002 Mar; 90 (3): 144-9
57. Grasmader K, Verwohlt PL, Rietschel M, et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004 Jul; 60 (5): 329-36
58. DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41 (15): 1247-66
59. RaoN. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007; 46 (4): 281-90
60. Bonnet U. Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. CNS Drug Rev 2002 Fall; 8 (3): 283-308
61. Mihara K, Otani K, Tybring G, et al. The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients. J Clin Psychopharmacol 1997 Dec; 17 (6): 467-71
62. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000 Dec; 39 (6): 413-27
63. Westra P, van Thiel MJ, Vermeer GA, et al. Pharmacokinetics of galanthamine (a long-acting anticholinesterase drug) in anaesthetized patients. Br J Anaesth 1986 Nov; 58 (11): 1303-7
64. Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41 (10): 719-39
65. Robinson DM, Keating GM. Memantine: a review of its use in Alzheimer's disease. Drugs 2006; 66 (11): 1515-34
66. Abernethyl DR, Divoll M, Greenblatt DJ, et al. Absolute bioavailability of imipramine: influence of food. Psychopharmacology (Berl) 1984; 83 (1): 104-6
67. Blin O. The pharmacokinetics of pergolide in Parkinson's disease. Curr Opin Neurol 2003 Dec; 16 Suppl. 1: S9-12
68. Reynolds Jr NC, Miska RM. Safety of anticonvulsants in hepatic porphyrias. Neurology 1981 Apr; 31 (4): 480-4
69. Chounta A, Tsiodras S, Zouridakis S, et al. Sibutramine use associated with reverible hepatotoxicity. Ann Intern Med 2005 Nov 15; 143 (10): 763-4
70. Mehta H, Murray B, LoIudice TA. Hepatic dysfunction due to intravenous abuse of methylphenidate hydrochloride. J Clin Gastroenterol 1984 Apr; 6 (2): 149-51
71. Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol 1987; 26 (2): 73-83
72. Chitturi S, George J. Hepatotoxicity of commonly used drugs: nonsteroidal anti-inflammatory drugs, antihypertensives, antidiabetic agents, anticonvulsants, lipidlowering agents, psychotropic drugs. Semin Liver Dis 2002; 22 (2): 169-83
73. Kellermann K, Soditt V, Rambeck B, et al. Fatal hepatotoxicity in a child treated with vigabatrin. Acta Neurol Scand 1996 May; 93 (5): 380-1
74. Sauve G, Bresson-Hadni S, Prost P, et al. Acute hepatitis after lamotrigine administration. Dig Dis Sci 2000 Sep; 45 (9): 1874-7
75. Bjoro K, Gjerstad L, Bentdal O, et al. Topiramate and fulminant liver failure [letter]. Lancet 1998 Oct 3; 352 (9134): 1119
76. Lasso-de-La-Vega MC, Zapater P, Such J, et al. Gabapentin- associated hepatotoxicity. Am J Gastroenterol 2001 Dec; 96 (12): 3460-2
77. Richardson CE, Williams DW, Kingham JG. Gabapentin induced cholestasis. BMJ 2002 Sep 21; 325 (7365): 635
78. Brockmann K, Hanefeld F. Progressive elevation of liver enzymes in a child treated with sulthiame. Neuropediatrics 2001 Jun; 32 (3): 165-6
79. Hubble JP, Koller WC, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995 Aug; 18 (4): 338-47
80. Maxwell JD, Carrella M, Parkes JD, et al. Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis. Clin Sci 1972 Aug; 43 (2): 143-51
81. Dincsoy HP, Saelinger DA. Haloperidol-induced chronic cholestatic liver disease. Gastroenterology 1982 Sep; 83 (3): 694-700
82. Ozcanli T, Erdogan A, Ozdemir S, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry 2006 Aug 30; 30 (6): 1163-6
83. El Hajj I, Sharara AI, Rockey DC. Subfulminant liver failure associated with quetiapine. Eur J Gastroenterol Hepatol 2004 Nov; 16 (12): 1415-8
84. Cohen LS, Cohen DE. Lithium-induced hyperbilirubinemia in an adolescent. J Clin Psychopharmacol 1991 Aug; 11 (4): 274-5
85. Hazelwood RE. Ascites: a side effect of lithium [letter]? Am J Psychiatry 1981 Feb; 138 (2): 257
86. Krebs S, Dormann H, Muth-Selbach U, et al. Risperidoneinduced cholestatic hepatitis. Eur J Gastroenterol Hepatol 2001 Jan; 13 (1): 67-9
87. Morgan DD, Robinson JD, Mendenhall CL. Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis. Eur J Clin Pharmacol 1981 Mar; 19 (4): 279-85
88. Karsenti D, Blanc P, Bacq Y, et al. Hepatotoxicity associated with zolpidem treatment. BMJ 1999 May 1; 318 (7192): 1179
89. van Vliet AC, Frenkel M, Wilson JH. Acute liver necrosis after treatment with opipramol. Ned Tijdschr Geneeskd 1977 Aug 20; 121 (34): 1325-7
90. Cai Q, Benson MA, Talbot TJ, et al. Acute hepatitis due to fluoxetine therapy. Mayo Clin Proc 1999 Jul; 74 (7): 692-4
91. Lopez-Torres E, Lucena MI, Seoane J, et al. Hepatotoxicity related to citalopram. Am J Psychiatry 2004 May; 161 (5): 923-4
92. Green BH. Fluvoxamine and hepatic function. Br J Psychiatry 1988 Jul; 153: 130-1
93. Timmings P, Lamont D. Intrahepatic cholestasis associated with moclobemide leading to death. Lancet 1996 Mar 16; 347 (9003): 762-3
94. Otani K, Kaneko S, Tasaki H, et al. Hepatic injury caused by mianserin. BMJ 1989 Aug 19; 299 (6697): 519
95. Hui CK, Yuen MF, Wong WM, et al. Mirtazapine-induced hepatotoxicity. J Clin Gastroenterol 2002 Sep; 35 (3): 270-1
96. Horsmans Y, De Clercq M, Sempoux C. Venlafaxineassociated hepatitis [letter]. Ann Intern Med 1999 Jun 1; 130 (11): 944
97. Cardona X, Avila A, Castellanos P. Venlafaxine-associated hepatitis [letter]. Ann Intern Med 2000 Mar 7; 132 (5): 417
98. Hu KQ, Tiyyagura L, Kanel G, et al. Acute hepatitis induced by bupropion. Dig Dis Sci 2000 Sep; 45 (9): 1872-3
99. Alvaro D, Onetti-Muda A, Moscatelli R, et al. Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking: a case report. Dig Liver Dis 2001 Nov; 33 (8): 703-6
100. Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. Aliment Pharmacol Ther 2007 Feb 15; 25 (4): 471-6
101. Alvin J, McHorse T, Hoyumpa A, et al. The effect of liver disease in man on the disposition of phenobarbital. J Pharmacol Exp Ther 1975 Jan; 192 (1): 224-35
102. Pisani F, Perucca E, Primerano G, et al. Single-dose kinetics of primidone in acute viral hepatitis. Eur J Clin Pharmacol 1984; 27 (4): 465-9
103. Blaschke TF, Meffin PJ, Melmon KL, et al. Influence of acute viral hepatitis on phenytoin kinetics and protein binding. Clin Pharmacol Ther 1975 Jun; 17 (6): 685-91
104. Pacifici GM, Viani A, Rizzo G, et al. Plasma protein binding of clonazepam in hepatic and renal insufficiency and after hemodialysis. Ther DrugMonit 1987 Dec; 9 (4): 369-73
105. Vasudevan AE, Goh KL, Bulgiba AM. Impairment of psychomotor responses after conscious sedation in cirrhotic patients undergoing therapeutic upper GI endoscopy. Am J Gastroenterol 2002 Jul; 97 (7): 1717-21
106. Klotz U, Rapp T, Muller WA. Disposition of valproic acid in patients with liver disease. Eur J Clin Pharmacol 1978 Mar 17; 13 (1): 55-60
107. Krahenbuhl S, Brandner S, Kleinle S, et al. Mitochondrial diseases represent a risk factor for valproate-induced fulminant liver failure. Liver 2000 Jul; 20 (4): 346-8
108. Marcellin P, de Bony F, Garret C, et al. Influence of cirrhosis on lamotrigine pharmacokinetics. Br J Clin Pharmacol 2001 May; 51 (5): 410-4
109. Brockmoller J, Thomsen T, Wittstock M, et al. Pharmacokinetics of levetiracetam in patients with moderate to severe liver cirrhosis (Child-Pugh classes A, B, and C): characterization by dynamic liver function tests. Clin Pharmacol Ther 2005 Jun; 77 (6): 529-41
110. Whiteman PD, Fowle AS, Hamilton MJ, et al. Pharmacokinetics and pharmacodynamics of procyclidine in man. Eur J Clin Pharmacol 1985; 28 (1): 73-8
111. Jorga KM, Kroodsma JM, Fotteler B, et al. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites. Clin Pharmacol Ther 1998 Jun; 63 (6): 646-54
112. Read AE, Laidlaw J, McCarthy CF. Effects of chlorpromazine in patients with hepatic disease. Br Med J 1969 Aug 30; 3 (5669): 497-9
113. Hu OY, Tang HS, Sheeng TY, et al. Pharmacokinetics of promazine: I. Disposition in patients with acute viral hepatitis B. Biopharm Drug Dispos 1990 Oct; 11 (7): 557-68
114. Hu OY, Tang HS, Sheeng TY, et al. Pharmacokinetics of promazine in patients with hepatic cirrhosis:correlation with a novel galactose single point method. J Pharm Sci 1995 Jan; 84 (1): 111-4
115. Zhang WV, Ramzan I, Murray M. Impaired microsomal oxidation of the atypical antipsychotic agent clozapine in hepatic steatosis. J Pharmacol Exp Ther 2007 Aug; 322 (2): 770-7
116. Thyrum PT, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuropsychopharmacol Biol Psychiatry 2000 May; 24 (4): 521-33
117. Snoeck E, Van PeerA, Sack M, et al. Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man. Psychopharmacology (Berl) 1995 Dec; 122 (3): 223-9
118. Klotz U, Antonin KH, Brugel H, et al. Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clin Pharmacol Ther 1977 Apr; 21 (4): 430-6
119. Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest 1975 Feb; 55 (2): 347-59
120. Andreasen PB, Hendel J, Greisen G, et al. Pharmacokinetics of diazepam in disordered liver function. Eur J Clin Pharmacol 1976 Jun 15; 10 (2): 115-20
121. Branch RA, Morgan MH, James J, et al. Intravenous administration of diazepam in patients with chronic liver disease. Gut 1976 Dec; 17 (12): 975-83
122. Bozkurt P, Kaya G, Suzer O, et al. Diazepam serum concentration-sedative effect relationship in patients with liver disease. Middle East J Anesthesiol 1996 Feb; 13 (4): 405-13
123. Sellers EM, Greenblatt DJ, Giles HG, et al. Chlordiazepoxide and oxazepam disposition in cirrhosis. Clin Pharmacol Ther 1979 Aug; 26 (2): 240-6
124. Roberts RK, Wilkinson GR, Branch RA, et al. Effect of age and parenchymal liver disease on the disposition and elimination of chlordiazepoxide (librium). Gastroenterology 1978 Sep; 75 (3): 479-85
125. Shull HJ, Wilkinson GR, Johnson R, et al. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Ann Intern Med 1976 Apr; 84 (4): 420-5
126. Kraus JW, Desmond PV, Marshall JP, et al. Effects of aging and liver disease on disposition of lorazepam. Clin Pharmacol Ther 1978 Oct; 24 (4): 411-9
127. Monjanel-Mouterde S, Antoni M, Bun H, et al. Pharmacokinetics of a single oral dose of clobazam in patients with liver disease. Pharmacol Toxicol 1994 Jun; 74 (6): 345-50
128. Juhl RP, Van Thiel DH, Dittert LW, et al. Alprazolam pharmacokinetics in alcoholic liver disease. J Clin Pharmacol 1984 Feb-Mar; 24 (2-3): 113-9
129. Dalhoff K, Poulsen HE, Garred P, et al. Buspirone pharmacokinetics in patients with cirrhosis. Br J Clin Pharmacol 1987 Oct; 24 (4): 547-50
130. Barbhaiya RH, Shukla UA, Pfeffer M, et al. Disposition kinetics of buspirone in patients with renal or hepatic impairment after administration of single and multiple doses. Eur J Clin Pharmacol 1994; 46 (1): 41-7
131. Jochemsen R, Van Beusekom BR, Spoelstra P, et al. Effect of age and liver cirrhosis on the pharmacokinetics of nitrazepam. Br J Clin Pharmacol 1983 Mar; 15 (3): 295-302
132. Drouet-Coassolo C, Iliadis A, Coassolo P, et al. Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. Fundam Clin Pharmacol 1990; 4 (6): 643-51
133. Bakti G, Fisch HU, Karlaganis G, et al. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987 Jul-Aug; 7 (4): 629-38
134. Kroboth PD, Smith RB, Van Thiel DH, et al. Nighttime dosing of triazolam in patients with liver disease and normal subjects: kinetics and daytime effects. J Clin Pharmacol 1987 Aug; 27 (8): 555-60
135. Robin DW, LeeM, Hasan SS, et al. Triazolam in cirrhosis: pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 1993 Dec; 54 (6): 630-7
136. HildebrandM, Hellstern A, HumpelM, et al. Plasma levels and urinary excretion of lormetazepam in patients with liver cirrhosis and in healthy volunteers. Eur J Drug Metab Pharmacokinet 1990 Jan-Mar; 15 (1): 19-26
137. Ghabrial H, Desmond PV, Watson KJ, et al. The effects of age and chronic liver disease on the elimination of temazepam. Eur J Clin Pharmacol 1986; 30 (1): 93-7
138. Ochs HR, Greenblatt DJ, Verburg-Ochs B, et al. Temazepam clearance unaltered in cirrhosis. Am J Gastroenterol 1986 Jan; 81 (1): 80-4
139. Trouvin JH, Farinotti R, Haberer JP, et al. Pharmacokinetics of midazolam in anaesthetized cirrhotic patients. Br J Anaesth 1988 Jun; 60 (7): 762-7
140. MacGilchrist AJ, Birnie GG, Cook A, et al. Pharmacokinetics and pharmacodynamics of intravenous midazolam in patients with severe alcoholic cirrhosis. Gut 1986 Feb; 27 (2): 190-5
141. Pentikainen PJ, Valisalmi L, Himberg JJ, et al. Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 1989 Mar; 29 (3): 272-7
142. Chalasani N, Gorski JC, Patel NH, et al. Hepatic and intestinal cytochrome P450 3A activity in cirrhosis: effects of transjugular intrahepatic portosystemic shunts. Hepatology 2001 Dec; 34 (6): 1103-8
143. Parker G, Roberts CJ. Plasma concentrations and central nervous system effects of the new hypnotic agent zopiclone in patients with chronic liver disease. Br J Clin Pharmacol 1983 Sep; 16 (3): 259-65
144. Meredith CG, Christian Jr CD, et al. Diphenhydramine disposition in chronic liver disease. Clin Pharmacol Ther 1984 Apr; 35 (4): 474-9
145. Pentikainen PJ, Neuvonen PJ, Jostell KG. Pharmacokinetics of chlormethiazole in healthy volunteers and patients with cirrhosis of the liver. Eur J Clin Pharmacol 1980 Apr; 17 (4): 275-84
146. Centerholt C, Ekblom M, Odergren T, et al. Pharmacokinetics and sedative effects in healthy subjects and subjects with impaired liver function after continuous infusion of clomethiazole. Eur J Clin Pharmacol 2003 Jun; 59 (2): 117-22
147. Hrdina PD, Lapierre YD, Koranyi EK. Altered amitriptyline kinetics in a depressed patient with porto-caval anastomosis. Can J Psychiatry 1985 Mar; 30 (2): 111-3
148. Benfield P, Heel RC, Lewis SP. Fluoxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1986 Dec; 32 (6): 481-508
149. Schenker S, Bergstrom RF, Wolen RL, et al. Fluoxetine disposition and elimination in cirrhosis. Clin Pharmacol Ther 1988 Sep; 44 (3): 353-9
150. Joffe P, Larsen FS, Pedersen V, et al. Single-dose pharmacokinetics of citalopram in patients with moderate renal insufficiency or hepatic cirrhosis compared with healthy subjects. Eur J Clin Pharmacol 1998 May; 54 (3): 237-42
151. Dalhoff K, Almdal TP, Bjerrum K, et al. Pharmacokinetics of paroxetine in patients with cirrhosis. Eur J Clin Pharmacol 1991; 41 (4): 351-4
152. Demolis JL, Angebaud P, Grange JD, et al. Influence of liver cirrhosis on sertraline pharmacokinetics. Br J Clin Pharmacol 1996 Sep; 42 (3): 394-7
153. van Harten J, Duchier J, Devissaguet JP, et al. Pharmacokinetics of fluvoxamine maleate in patients with liver cirrhosis after single-dose oral administration. Clin Pharmacokinet 1993 Feb; 24 (2): 177-82
154. Areberg J, Christophersen JS, Poulsen MN, et al. The pharmacokinetics of escitalopram in patients with hepatic impairment. AAPS J 2006; 8 (1): E14-9
155. Stoeckel K, Pfefen JP,MayersohnM, et al. Absorption and disposition of moclobemide in patients with advanced age or reduced liver or kidney function. Acta Psychiatr Scand Suppl 1990; 360: 94-7
156. Timmer CJ, Sitsen JM, Delbressine LP. Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet 2000 Jun; 38 (6): 461-74
157. Tran A, Laneury J, Duchê ne P, et al. Pharmacokinetics of reboxetine in volunteers with hepatic impairment. Clin Drug Invest 2000; 19 (6): 473-7
158. DeVane CL, Laizure SC, Stewart JT, et al. Disposition of bupropion in healthy volunteers and subjects with alcoholic liver disease. J Clin Psychopharmacol 1990 Oct; 10 (5): 328-32
159. Zhao Q, Iyer GR, Verhaeghe T, et al. Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers. J Clin Pharmacol 2002 Apr; 42 (4): 428-36
160. Reyes JF, Vargas R, Kumar D, et al. Steady-state pharmacokinetics, pharmacodynamics and tolerability of donepezil hydrochloride in hepatically impaired patients. Br J Clin Pharmacol 2004 Nov; 58 Suppl. 1: 9-17
161. Tiseo PJ, Vargas R, Perdomo CA, et al. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function. Br J Clin Pharmacol 1998 Nov; 46 Suppl. 1: 51-5
162. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973 Aug; 60 (8): 646-9
163. Wilkinson GR. Clearance approaches in pharmacology. Pharmacol Rev 1987 Mar; 39 (1): 1-47
164. Ito K, Houston JB. Comparison of the use of liver models for predicting drug clearance using in vitro kinetic data from hepatic microsomes and isolated hepatocytes. Pharm Res 2004 May; 21 (5): 785-92
165. Frye RF, Zgheib NK, Matzke GR, et al. Liver disease selectively modulates cytochrome P450-mediated metabolism. Clin Pharmacol Ther 2006 Sep; 80 (3): 235-45
166. George J,MurrayM, BythK, et al.Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 1995 Jan; 21 (1): 120-8
167. Branch RA. Drugs in liver disease. Clin Pharmacol Ther 1998 Oct; 64 (4): 462-5